Die Ophthalmologie · 2026
[Topical atropine for myopia prevention : Current study situation].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gross Isabella Silke Elisabeth, Farassat Navid
Аннотация
BACKGROUND: Low-dose atropine has emerged as an effective intervention for myopia control in children; however, for a long time the evidence predominantly originated from East Asia.
OBJECTIVE: This article reviews the efficacy, safety, dose-finding and regulatory approval status of topical atropine for myopia control, with particular focus on European populations.
MATERIAL AND METHODS: Narrative review of selected RCT (randomized controlled trials), meta-analyses, long-term data and regulatory approval information.
RESULTS: Atropine 0.01-0.05% dose-dependently reduces myopia progression. The effects of a 0.01% monotherapy are small to moderate. With Ryjunea® (Santen Pharmaceutical Co., Ltd., Osaka, Japan), a preparation was approved in Europe for the first time in 2025.
CONCLUSION: Topical atropine is effective and well tolerated. Unresolved questions regarding dosing in non-Asian populations, treatment duration and long-term effects on complications should be addressed by further studies.
OBJECTIVE: This article reviews the efficacy, safety, dose-finding and regulatory approval status of topical atropine for myopia control, with particular focus on European populations.
MATERIAL AND METHODS: Narrative review of selected RCT (randomized controlled trials), meta-analyses, long-term data and regulatory approval information.
RESULTS: Atropine 0.01-0.05% dose-dependently reduces myopia progression. The effects of a 0.01% monotherapy are small to moderate. With Ryjunea® (Santen Pharmaceutical Co., Ltd., Osaka, Japan), a preparation was approved in Europe for the first time in 2025.
CONCLUSION: Topical atropine is effective and well tolerated. Unresolved questions regarding dosing in non-Asian populations, treatment duration and long-term effects on complications should be addressed by further studies.